厄洛替尼在晚期非小细胞肺癌中的临床应用分析

目的 探讨厄洛替尼在晚期非小细胞肺癌（NSCLC）患者中的应用价值.方法 选择晚期NSCLC（腺癌和鳞癌）患者,腺癌和鳞癌患者均分为未治疗组、化疗组、靶向治疗组及化疗＋靶向治疗组.靶向治疗服用厄洛替尼.通过生存分析比较各组中位无进展生存期（PFS）及中位总生存期（OS）.结果 肺腺癌及肺非腺癌各自的四组间,中位PFS、OS均存在统计学差异,靶向治疗组中位PFS、OS均较未治疗组的长.肺腺癌患者中,表皮生长因子受体（EGFR）基因突变型组和野生型组的中位OS差别有统计学意义.结论 厄洛替尼治疗的晚期NSCLC患者中位PFS及OS较未治疗者长;厄洛替尼治疗的肺腺癌患者,EGFR基因突变型者中位OS较野生型者长.

Analysis on clinical application of erlotinib in patients with advanced non-small cell lung cancer

Objective To investigate the application value of erlotinib in patients with advanced non-small cell lung cancer. Methods Patients with advanced NSCLC （adenocarcinoma and squamous cell carcinoma） were selected, ade- nocarcinoma and squamous cell carcinoma patients were all divided into untreated group, chemotherapy group,target- ed therapy group and chemotherapy combinated with targeted therapy group,targeted therapy group were taken er- lotinib . The median progression-free survival （PFS） and the median overall survival （OS） of each group were com- pared by survival analysis. Results Among the respective four groups of adenocarcinoma and squamous cell carcinoma patients,their median PFS and median OS were all statistically different,their targeted therapy groups had longer me- dian PFS and median OS than the untreated groups.Among the patients with lung adenocarcinoma,the epidermal growth factor receptor （EGFR） gene mutations group and wild-type group＇s median OS difference was statistically significant. Conclusion Among the patients with advanced NSCLC ,the median PFS and the median OS of erlotinib treatment were longer than that with no treatment; Among the patients with lung adenocarcinoma treated by erlotinib, patients with EGFR gene mutations had longer median OS than that with wild-type gene.